| Autor: |
Babish JG; a Bionexus, Ltd., 53 Brown Road, Suite B, Ithaca, NY 14850, USA., Dahlberg CJ; b Hughes Center for Research and Innovation, Nature's Sunshine Products, 2500 Executive Parkway, Lehi, UT 84043, USA., Ou JJ; b Hughes Center for Research and Innovation, Nature's Sunshine Products, 2500 Executive Parkway, Lehi, UT 84043, USA., Keller WJ; b Hughes Center for Research and Innovation, Nature's Sunshine Products, 2500 Executive Parkway, Lehi, UT 84043, USA., Gao W; b Hughes Center for Research and Innovation, Nature's Sunshine Products, 2500 Executive Parkway, Lehi, UT 84043, USA., Kaadige MR; b Hughes Center for Research and Innovation, Nature's Sunshine Products, 2500 Executive Parkway, Lehi, UT 84043, USA., Brabazon H; b Hughes Center for Research and Innovation, Nature's Sunshine Products, 2500 Executive Parkway, Lehi, UT 84043, USA., Lamb J; b Hughes Center for Research and Innovation, Nature's Sunshine Products, 2500 Executive Parkway, Lehi, UT 84043, USA., Soudah HC; d Premier Medical Specialists, Stella Maris Obesity Medicine, Tenet Healthcare System, 2315 Dougherty Ferry Rd., Suite 109, St. Louis, MO 63122, USA.; e Washington University School of Medicine, St. Louis, 660 S Euclid Ave, St. Louis, MO 63110, USA., Kou X; c Nature's Sunshine Products, 1655 North Main St., Spanish Fork, UT 84660, USA., Zhang Z; c Nature's Sunshine Products, 1655 North Main St., Spanish Fork, UT 84660, USA., Pacioretty LM; a Bionexus, Ltd., 53 Brown Road, Suite B, Ithaca, NY 14850, USA., Tripp ML; b Hughes Center for Research and Innovation, Nature's Sunshine Products, 2500 Executive Parkway, Lehi, UT 84043, USA. |
| Abstrakt: |
We examined the clinical safety and efficacy of F105 in 11 subjects with moderate dyslipidemia. F105 is a combination of bergamot fruit extract (Citrus bergamia, BFE) and 9 phytoextracts selected for their ability to improve the antioxidant and anti-inflammatory activity of BFE. In vitro F105 exhibited a synergistic inhibition of oxygen radical absorbing capacity, peroxynitrite formation, and myeloperoxidase activity. Following 12 weeks of F105 daily, no treatment-related adverse events or changes in body mass were seen. Statistically significant changes were noted in total cholesterol (-7.3%), LDL-cholesterol (-10%), non-HDL cholesterol (-7.1%), cholesterol/HDL (-26%), and apolipoprotein B (-2.8%). A post hoc analysis of 8 subjects with HbA1c > 5.4 and HOMA-IR score > 2 or elevated triglycerides revealed additional statistically significant changes in addition to those previously observed in all subjects including triglycerides (-27%), oxLDL (-19%), LDL/HDL (-25%), triglycerides/HDL (-27%), oxLDL/HDL (-25%), and PAI-1 (-37%). A follow-up case report of a 70-year-old female patient, nonresponsive to statin therapy and placed on F105 daily, demonstrated improved cardiometabolic variables over 12 weeks similar to the subgroup. In summary, F105 was clinically well-tolerated and effective for ameliorating dyslipidemia in subjects with moderate cardiometabolic risk factors, particularly in the individuals with HbA1c > 5.4%. |
